Sorafenib is drug approved for the treatment of a form of liver cancer called hepatocellular carcinoma (HCC). Doxorubicin is an anticancer drug commonly used to treat a variety of cancers. In this study, investigators want to determine if adding doxorubicin to sorafenib is more effective than sorafenib alone for patients with advanced HCC that has spread and has not responded to treatments such as surgery or local therapies.
Sorafenib is taken orally (by mouth). Doxorubicin is given by vein. Patients will be randomly assigned to receive sorafenib alone or with doxorubicin.
This study is sponsored by the National Cancer Institute, who will provide sorafenib for all patients in the study.